Abstract
Background There is limited information on the role of different age groups in propagating SARS-CoV-2 epidemics driven by the Omicron variants.
Methods We examined the role of individuals in different age groups in propagating the Spring, Summer, and Autumn waves of the Omicron epidemics in France using the previously developed methodology based on the relative risk (RR) statistic that measures the change in the group’s proportion among all cases admitted to ICU for COVID-19 before vs. after the peak of an epidemic wave. Higher value of the RR statistic for a given age group suggests a disproportionate depletion of susceptible individuals in that age group during the epidemic’s ascent (due to increased contact rates and/or susceptibility to infection).
Results For the Spring wave (March 14 - May 15), the highest RR estimate belonged to children aged 10-19y (RR=1.92 (95% CI (1.18,3.12)), followed by adults aged 40-49y (RR=1.45 (1.09,1.93)) and children aged 0-9y (RR=1.31 (0.98,1.74)). For the Summer wave (June 27 – Aug. 21), the highest RR estimate belonged to children aged 0-9y (RR=1.61 (1.12,2.3)) followed by children aged 10-19y (RR=1.46 (0.72,2.93)) and adults aged 20-29y (RR=1.42 (0.91,2.23)). For the Autumn wave (Sep. 18 – Nov. 12), the highest RR estimate belonged to children aged 10-19y (RR=1.63 (0.72,3.71)), followed by adults aged 30-34y (RR=1.34 (0.8,2.25)) and 20-24y (RR=1.20 (0.65,2.21)).
Conclusions Children aged 10-19y played the greatest relative role in propagating Omicron epidemics, particularly when schools were open, followed by children aged 0-9y and adults aged 20-29y, as well as adults aged 30-49y. Persons aged over 50y played a more limited role in propagating Omicron infection in the community. Additional efforts are needed to increase vaccination coverage in children aged 10-19y, as well as younger children and young adults to mitigate Omicron epidemics in the community.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
edmigo3{at}gmail.com
Data Availability
This study is based on aggregate, de-identified, publicly available data that can be accessed through refs. 11-13
https://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19/
https://www.insee.fr/fr/statistiques/2381472#graphique-Donnes
